Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The new triptans.

¹Department of Medicine/Neurology, University of Toronto, Toronto, Ontario, Canada. marek.gawel@sunnybrook.on.ca

The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique

|September 24, 1999

Summary

This summary is machine-generated.

New triptan compounds offer acute migraine treatment by targeting serotonin receptors. These drugs constrict blood vessels and reduce neurogenic inflammation for migraine relief.

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

New Classification of Headache: A more accurate method of diagnosis.

Canadian family physician Medecin de famille canadien·2011

Same author

Clinical features and pharmacological treatment of migraine patients referred to headache specialists in Canada.

Cephalalgia : an international journal of headache·2006

Same author

Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine.

Headache·2004

Same author

Eletriptan.

Expert opinion on investigational drugs·2002

Same author

A systematic review of the use of triptans in acute migraine.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2001

Same author

Oral zolmitriptan is effective in the acute treatment of cluster headache.

Neurology·2000

Same journal

A review of substance abuse monitoring in a social services context: a primer for child protection workers.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010

Same journal

Safety and efficacy of tegaserod therapy in patients with irritable bowel syndrome or chronic constipation.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010

Same journal

The impact of an ADHD co-morbidity on the diagnosis of FASD.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010

Same journal

Profile of the first 1,400 patients receiving diagnostic evaluations for fetal alcohol spectrum disorder at the Washington State Fetal Alcohol Syndrome Diagnostic & Prevention Network.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010

Same journal

Managing fetal alcohol spectrum disorder in the public school system: a needs assessment pilot.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010

Same journal

Acute intravascular haemolysis associated with intravenous administration of meropenem in a sixty four year old man.

The Canadian journal of clinical pharmacology = Journal canadien de pharmacologie clinique·2010

See all related articles

Area of Science:

Neurology
Pharmacology

Background:

Migraine is a debilitating neurological condition.
Acute treatment options have evolved over the past decade.

Purpose of the Study:

To summarize new compounds for acute migraine treatment.
To review the pharmacology and clinical properties of triptans.

Main Methods:

Review of studies on triptans.
Comparison of triptan pharmacology and clinical properties.

Main Results:

Triptans are serotonin-derived compounds.
They act on 5-hydroxytryptamine 1B/1D receptors.
Activation leads to vasoconstriction, reduced inflammation, and inhibited neuronal discharge.

Conclusions:

Triptans represent a significant advancement in acute migraine therapy.
Specific triptans reviewed include sumatriptan, zolmitriptan, naratriptan, rizatriptan, and eletriptan.